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The human ribonuclease RNase 7 has been originally isolated from human skin and
is a member of the human RNase A superfamily. RNase 7 is constantly released by
keratinocytes and accumulates on the skin surface. The expression of RNase 7 in
keratinocytes can be induced by diverse stimuli such as cytokines, growth factors, and
microbial factors. RNase 7 exhibits a potent broad spectrum of antimicrobial activity
against various microorganisms and contributes to control bacterial growth on the skin
surface. The ribonuclease and antimicrobial activity of RNase 7 can be blocked by the
endogenous ribonuclease inhibitor. There is also increasing evidence that RNase 7 exerts
immunomodulatory activities and may participate in antiviral defense. In this review, we
discuss how these characteristics of RNase 7 contribute to innate cutaneous defense
and highlight its role in skin infection and inflammation. We also speculate how a potential
dysregulation of RNase 7 promotes inflammatory skin diseases and if RNase 7 may have
therapeutic potential.
Keywords: RNase 7, antimicrobial ribonucleases, RNA, innate immunity, cutaneous defense, skin infection, skin
inflammation
INTRODUCTION
Human skin is permanently in contact with microorganisms. Among these microorganisms are
many beneficial members of the microbiota. In addition, the skin has to deal with potential
pathogenic microorganisms causing partially severe skin infections. There is increasing evidence
that antimicrobial peptides and proteins (AMP) control the growth of microorganisms on all
epithelial tissues including skin. AMP may play an important role to shape and control the
preferred microbiota as well as to protect the skin from pathogenic microorganisms. Human
skin is able to produce different types of AMP that exhibit individual activity profiles. One
major AMP expressed by keratinocytes and released on the skin surface is the ribonuclease
RNase 7. RNase 7 belongs to the human RNase A superfamily which consists of 13 genes
located on chromosome 14 and contains eight different members with RNase activities
(RNase 1–8) (1). The RNase A superfamily is named after its founding member, bovine
pancreatic ribonuclease (RNase A). The members of this family contain an RNase catalytic
domain that is composed of one lysine and two histidine residues. The protein structure is
characterized by eight cysteine residues which are connected via four disulfide bridges (1).
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A huge repertoire of diverse physiological functions of these
RNases has been reported during the last decades. Examples
are angiogenic, neurotoxic, and diverse immunomodulatory
activities (2). Several members of the human RNase A
superfamily are also characterized by antimicrobial activities
and there is increasing evidence that they participate in innate
immunity. In particular, RNase 2 (also termed eosinophil-derived
neurotoxin, EDN) and RNase 3 (also termed eosinophil cationic
protein, ECP) exhibit diverse antiviral and antibacterial activities
as well as immunomodulatory activities suggesting an important
role in innate host defense (3, 4). Moreover, antimicrobial
activities have also been reported for RNase 5 (also named
angiogenin due to its angiogenic potency) (4–6), RNase 6 (7),
RNase 7 (8, 9), and RNase 8 (10). RNase 5 and RNase 7 are
both expressed by keratinocytes and thus may contribute to
cutaneous innate defense (6, 11). Indeed, there is increasing
evidence that RNase 7 may play an important role to protect skin
from infection (8). This review aims to summarize the current
knowledge about the physiological activities of RNase 7 and to
highlight its role in cutaneous host defense.
EXPRESSION AND INDUCTION OF RNase
7 IN SKIN
Site of RNase 7 Expression
The RNase 7 protein has been originally isolated from stratum
corneum extracts during an attempt to identify and characterize
the antimicrobial factors produced by human healthy skin (12).
As the name implies, it is the seventh member of the human
RNase A superfamily and exhibits ribonuclease activity. It has
a molecular mass of 14.5 kDa and is highly cationic due to the
presence of many arginine and lysine residues (12). Isolation
of the protein from human skin and subsequent cloning of the
corresponding cDNA enabled the identification of RNase 7 gene
expression in human skin-derived keratinocytes (12). Of note,
RNase 7 is not only expressed in human skin. Gene expression
analyses revealed expression in various tissues such as heart, liver,
kidney, pharynx, and tonsil (12, 13). In addition, the group of
Spencer et al. identified a major role of RNase 7 in kidney and
bladder host defense (14, 15).
Immunostaining of skin biopsies revealed RNase 7 expression
in the keratinocytes throughout all epidermal layers with
an increased staining in the more differentiated uppermost
layers and an accumulation in the stratum corneum (12,
16). These data are in concordance with expression analyses
of cultured keratinocytes demonstrating a higher RNase 7
gene expression in differentiated cultures as compared with
proliferating keratinocytes (6). RNase 7 immunoreactivity was
also present in sebaceous glands and hair follicles (12, 17).
Analysis of skin rinsing fluids revealed the presence of RNase
7 throughout various body areas confirming the constitutive
expression and release of RNase 7 by keratinocytes (16, 18).
Interestingly, RNase 7 is also expressed in fetal skin suggesting
that RNase 7 may already control cutaneous microbial growth of
the fetus and newborn (19). In addition, RNase 7 may have other,
as yet unknown functions in fetal skin such as a regulatory role in
development. However, this hypothesis remains to be proven.
Induction of RNase 7 Expression
In addition to the constitutive expression, RNase 7 expression
in keratinocytes can be induced by various stimuli and
different signal transduction pathways (summarized in Figure 1).
Proinflammatory cytokines such as IL-17A, interferon-gamma
and IL-1 are able to induce the expression of RNase 7 in
keratinocytes (12, 17, 20, 21). Especially the synergistic action
of proinflammatory cytokines such as IL-17A and interferon-
gamma markedly induced the expression of RNase 7 (20).
The synergistic induction of RNase 7 by IL-17A/interferon-
gamma was mediated by the signal transducer and activator of
transcription 3 (STAT3) (20). Mohammed et al. reported that the
induction of RNase 7 by IL-1beta in corneal epithelial cells was
mediated by TGFbeta-activated kinase-1 (TAK-1). This in turn
led to activation of the mitogen-activated protein kinase (MAPK)
pathway resulting in activation of the transcription factors c-
Jun and activating transcription factor 2 (ATF2). In contrast, the
NF-kappaB pathway had no major influence on the IL-1beta-
mediated induction of RNase 7 in corneal epithelial cells (21).
Induction of RNase 7 by pro-inflammatory cytokines was also
detected in the keratinocytes cell line HaCaT (22). Overall, the
induction of RNase 7 by proinflammatory cytokines suggests that
the local environment of inflammatory skin diseases like psoriasis
trigger the increased expression of RNase 7 (23, 24).
Since RNase 7 exhibits potent antimicrobial activity (see
below), it would be of biological significance that keratinocytes
respond with an increased RNase 7 expression to the presence
of microorganisms, in particular potential pathogens. Indeed,
the expression of RNase 7 in keratinocytes can be induced by
Staphylococcus (S.) aureus (25–28), Pseudomonas (P.) aeruginosa
(29), Enterococcus (E.) faecium (16), and the dermatophyte
Trichophyton (T.) rubrum (30). Of note, also skin commensals
such as Staphylococcus (S.) epidermidis and Corynebacterium
(C.) amycolatum induce RNase 7 expression in keratinocytes
indicating that the presence of commensals leads to an increased
RNase 7 production thereby strengthening cutaneous defense
(22, 27, 31). S. epidermidis also enhanced the S. aureus-induced
expression of RNase 7 in keratinocytes suggesting that the
presence of commensals amplifies the defense response of
human keratinocytes toward pathogens such as S. aureus (27).
Interestingly, the induction of RNase 7 by the skin commensals
S. epidermidis (27) and C. amycolatum (31), and by P. aeruginosa
(29) and T. rubrum (30) depends on the involvement of the
epidermal growth factor receptor (EGFR). This suggests that
the EGFR plays an important role in cutaneous defense by its
crucial role to mediate the expression of AMP such as RNase
7 and may offer an explanation for the increased susceptibility
for skin infections of cancer patients receiving anti-EGFR
therapy (32). Wanke et al. reported that—in addition to the
EGFR—also Toll-like receptor-2 (TLR-2) and the transcription
factor NF-kappaB are involved in the induction of RNase
7 in keratinocytes simulated with culture supernatants of S.
epidermidis. This is in contrast to S. aureus which has been
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FIGURE 1 | Regulation of RNase 7 induction. Shown are the proposed signal transduction pathways implicated in the induction of RNase 7 by microorganisms and
cytokines. Detailed explanations are given in the main text.
reported to activate the MAPK and phosphatidylinositol 3-
kinase/AKT signaling pathways to induce RNase 7 expression
(27). Thus, it seems that commensal and pathogenic bacteria
activate different signal transduction pathways to induce RNase 7
expression in keratinocytes. RNase 7 expression in keratinocytes
can also be induced by Borrelia burgdorferi, a bacterium that
causes Lyme borreliosis and is transmitted by Ixodes ticks.
Interestingly, tick saliva proteins have been shown to inhibit
the Borrelia burgdorferi-mediated induction of RNase 7 and
of other antimicrobial peptides and chemokines. This suggests
that components of the tick saliva inhibit cutaneous innate
defense reactions against Borrelia burgdorferi and thereby help
the bacterium to evade local host defense and to disseminate into
the body (33).
The role of cutaneous RNase 7 expression in the context
of viral infection is less explored. It has been reported that
keratinocytes infected with dengue virus showed an increased
RNase 7 expression. If this is a direct induction or indirectly
mediated by the release of inflammatory mediators is not clear.
In addition, if RNase 7 influences the infectivity by dengue virus
has not been reported (34). UV-B radiation also induces the
expression of RNase 7 and other AMP in keratinocytes. This
induction may contribute to the UV-mediated strengthening of
the innate immune response (35). Niacinamide has also been
identified as an inducer of the expression of RNase 7 and other
antimicrobial peptides in human keratinocytes. Niacinamide is a
well-known cosmetic ingredient and its antimicrobial peptides-
inducing capacity may account for its observed beneficial effects
on the skin barrier (36).
ANTIMICROBIAL AND RIBONUCLEASE
ACTIVITY
Antimicrobial Spectrum of RNase 7
A key feature of RNase 7 is its high antimicrobial activity
against a wide spectrum of microorganisms. In vitro studies
showed that RNase 7 is highly antimicrobial effective in low
micromolar concentrations against Gram-positive and Gram-
negative bacteria like S. aureus, P. aeruginosa, C. amycolatum, E.
faecium, Mycobacterium vaccae, the yeast Candida (C.) albicans
and Pichia pastoris and the dermatophyte T. rubrum (12, 16,
30, 37–41). The known microorganisms susceptible to RNase 7
are listed in Table 1 (6, 7, 12, 14–16, 25, 29–31, 37–50). The
functional relevance of the antimicrobial activity of RNase 7 and
its contribution to the antimicrobial capacity of stratum corneum
was demonstrated by the use of antibodies that neutralized the
antimicrobial activity of RNase 7. Using such antibodies, we could
show that inactivation of RNase 7 in human stratum corneum
extracts led to an increased outgrowth of P. aeruginosa, S. aureus,
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TABLE 1 | Overview of the microorganism susceptible to RNase 7.
Microorganism References
GRAM-POSITIVE BACTERIA
Staphylococcus aureus (12, 25, 37, 38, 42–46)
Staphylococcus saprophyticus (7, 47)
Enterococcus faecium (6, 12, 16, 44)
Enterococcus faecalis (6, 7, 48)
Propionibacterium acnes (12)
Micrococcus luteus (44)
Corynebacterium amycolatum (31)
Corynebacterium xerosis (31)
GRAM-NEGATIVE BACTERIA
Pseudomonas aeruginosa (12, 14, 29, 37, 44, 48, 49)
Escherichia coli (7, 12, 14, 15, 37, 44, 46–48)
Proteus mirabilis (13, 22)
Acinetobacter baumannii (44)
Klebsiella pneumoniae (14)
MYCOBACTERIA
Mycobacterium tuberculosis (50)
Mycobacterium vaccae (40)
YEAST
Candida albicans (12, 37, 41)
Pichia pastoris (37)
DERMATOPHYTES
Trichophyton rubrum (30, 39)
Trichophyton mentagrophytes (39)
Microsporum canis (39)
Epidermophyton floccosum (39)
C. amycolatum, and E. faecium. These results demonstrated that
RNase 7 is part of the growth control mechanism in the stratum
corneum (16, 25, 29, 31).
The Gram-positive bacterium S. aureus is a principal skin
pathogen causing many infectious cutaneous diseases. Our work
with ex vivo skin explants infected with S. aureus showed
an increased release of RNase 7 expression. Inhibition of the
antimicrobial activity of RNase 7 by specific antibodies resulted
in considerable outgrowth of S. aureus on the skin surface.
These results accentuate the functional relevance of RNase 7
in cutaneous defense against hazardous skin pathogens (25).
This goes in line with a study from Zanger et al. who analyzed
the RNase 7 expression levels of unaffected skin from healthy
control persons and subjects with a S. aureus skin infection after
a journey to a tropic or subtropic destination. They detected a
64% higher RNase 7 expression level in skin of the control group
than in the unaffected skin of the infected persons. These data
suggest that high RNase 7 baseline levels in healthy skin provide
an increased protection against S. aureus infection (51).
Antimicrobial Mechanisms of RNase 7 and
Influence of the Ribonuclease Inhibitor
As described above, RNase 7 is a member of the RNase A
superfamily and a potent ribonuclease that is able to degrade
RNA. This raises the question of whether the ribonuclease
activity is essential for the antimicrobial activity of RNase 7.
Huang et al. designed RNase 7 mutants (H15A, K38A, and
H123A) lacking ribonuclease activity and showed that these
mutants are still able to kill P. aeruginosa. In addition, they
identified three clusters of cationic residues on the surface of
RNase 7. Substitution experiments of cationic residues identified
the first N-terminal cluster with the lysine residues K1, K3,
K111, and K112 as essential for antimicrobial activity. The
other two clusters located on rigid secondary structures did not
influence antimicrobial activity of RNase 7 (37). In general, the
N-terminal cluster of RNases from the RNase A superfamily is
the conserved region responsible for their antimicrobial activity
(44). In line with the ribonuclease-independent killing activity
against P. aeruginosa, we constructed a recombinant RNase
7 mutant without ribonuclease activity and showed that this
mutant was still able to kill E. faecium (16). Ribonuclease-
independent antibacterial activity has also been described for
RNase 3/ECP (52).
The ribonuclease activity of RNases from the RNase A
superfamily can be inhibited by binding to the 50 kDa, cytosolic,
horseshoe-shaped Ribonuclease Inhibitor (RI) in a 1:1 molar
ratio. The RI forms tight complexes with the RNases which is
known as one of the tightest formation in biological systems
(53). It is an obvious question if binding of RI influences the
antimicrobial activity of RNase 7. Addition of RI to RNase
7 suspensions and subsequent testing of the killing capacity
of RNase 7 toward C. albicans and E. faecium resulted in a
reduced antimicrobial activity indicating that the RI blocks the
antimicrobial activity of RNase 7 (6). This inhibition may be
due to steric interaction and not due to specific inhibition
of the ribonuclease activity because the ribonuclease activity
is not essential for antibacterial killing as described above. In
concordance with these results, Spencer et al. also reported that
the RI bound to RNase 7 and inhibited its antimicrobial activity
by blocking its ability to bind the cell wall of uropathogenic
bacteria (54).
Immunohistochemical analysis revealed that the RI is located
mainly in the suprabasal epidermal layers but is absent in the
stratum corneum. In addition, incubation of the RI with stratum
corneum extracts led to the degradation of the RI suggesting
that proteolytic activity of the stratum corneum degrades the
RI (6). In contrast to the RI, RNase 7 is abundant in the
stratum corneum. This led to the hypothesis that in the epidermis
RNase 7 is complexed with the RI and thereby inactivated.
Degradation of the RI in the stratum corneum hinders RI-
mediated inactivation of RNase 7 thereby liberating RNase 7 to
function as antimicrobial factor (6, 55).
The exact mechanisms underlying the antimicrobial activity
of RNase 7 are not fully understood. Huang and coworkers
performed binding experiments with DNA-binding SYTOX R©
Green dye and showed that RNase 7 is able to bind to the
negatively charged membrane of P. aeruginosa and permeabilize
the bacterial membrane (37). Torrent et al. demonstrated by
means of liposome leakage assays that RNase 7 provokes
membrane disruption by binding to bacterial membranes.
Further experiments showed that RNase 7 did not interact with
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uncharged liposomes. Because of this fact the authors deduced
that this membrane interaction is electrostatically driven (56).
Further bacterial studies by this group showed a high leakage
affinity of RNase 7 for S. aureus and E. coli membranes. RNase
7 depolarized the membrane by binding to lipopolysaccharide
(LPS) and peptidoglycan, both major components of bacterial
cell membranes fromGram-positive andGram-negative bacteria,
respectively (46). Another study from Lin et al. identified OprI
(outer membrane protein I), an outer membrane lipoprotein
from P. aeruginosa, as the initial binding site for RNase 7
instead of LPS. Addition of exogenous OprI or an anti-OprI
antibody inhibited the antimicrobial activity of RNase 7 against
P. aeruginosa. The authors conclude that upon RNase 7 binding,
OprI internalizes along with RNase 7 into the cell leaving the cell
membrane permeable to metabolites (49). These studies suggest
that the interaction of RNase 7 with bacteria could be based on
a target specific accumulation to different bacterial lipoproteins.
This hypothesis needs to be proven in further studies with
other bacteria.
In addition to its antibacterial activity, RNase 7 exhibits also
activity against the yeast C. albicans. Salazar et al. described a
dual mode of action for RNase 3 and RNase 7 as antifungal
proteins against C. albicans. They designed mutants of both
RNases by depleting the active catalytic site at His15 which is
the complement to His12 and performed depolarization and
permeabilization membrane assays to assess the antimicrobial
action against C. albicans. They could show that both RNases act
first as membrane lytic proteins followed by enzymatic cellular
RNA degradation (41).
IMMUNOMODULATORY ACTIVITIES
Besides its antimicrobial activity, some studies provide evidence
for an additional immunomodulatory function of RNase 7.
Several members of the RNase A superfamily are well-known
for their immunomodulatory activities (2). Although the role of
RNase 7 as an immunomodulatory mediator is still emerging,
there is first evidence of immunomodulatory functions associated
with RNase 7. Resident and transiently migrating cells of the
immune system are present in healthy human skin. With regard
to antimicrobial defense, plasmacytoid dendritic cells (pDCs) are
considered to play a key role within the types of the dermal
immune system. pDCs usually circulate in the blood stream and
are present in lymph nodes. Under inflammatory conditions
they are able to infiltrate the skin (57). Due to their ability to
secrete a several times stronger interferon-alpha (IFNα) response
than any other cell types (58, 59), pDCs are crucial for cellular
antimicrobial defense. A recent study from Kopfnagel et al.
showed that RNase 7 in combination with human self-DNA
activates a potent IFNα response in pDCs (60). This finding is
in accordance with the known IFNα-inducing ability of LL-37
(61) and hBD-2/-3 (62) in complex with self-DNA. In addition,
comparative experiments revealed a markedly stronger IFNα
production in response to RNase 7 mixed with self-DNA as
compared to stimulation with LL-37 or hBD-2 in mixture with
self-DNA (60). Of note, the amount of the RNase 7-induced
IFNα release was high enough to efficiently protect human
keratinocytes from herpes simplex type I (HSV-I) infection.
This was of special significance because RNase 7 itself exhibits
no direct antiviral activity against HSV-I. In summary, this
study revealed the ability of RNase 7 to convert usually not
immunogenic self-DNA into a danger signal which enables a
strong immunomodulatory response (60). It remains to be shown
if these characteristics of RNase 7 may be linked with auto-
inflammatory diseases.
T cells are present in human skin under healthy and
inflammatory conditions. In healthy human skin they are
of importance in wound healing, stimulate production of
AMP by keratinocytes and influence keratinocyte development
(63). Under inflammatory conditions T cells present in
the blood can rapidly infiltrate the skin and produce pro-
inflammatory cytokines, like IL-4 or interferon-gamma (64).
A study of Kopfnagel et al. investigated the influence of
RNase 7 on Th2 cytokine production by human CD4+T
cells and Th2 cells. They reported that RNase 7 stimulation
lead to a significantly reduced Th2 cytokine release of IL-
4, IL-5, and IL-13. This downregulation of Th2 cytokines
was found to be mediated by a reduced activation of the
transcription factor GATA3. Interestingly, the ribonuclease
activity of RNase 7 was dispensable for this effect. Due to
this specific regulation the authors assumed a yet unknown
receptor-mediated process which needs to be elucidated in
further studies (65).
A novel study documents that RNase 7 mediates recognition
of self-DNA by human keratinocytes. Activation of keratinocytes
by a DNA/RNase 7 complex resulted in a markedly increased
release of the chemokine IP-10 (CXCL10), a process that was
mediated by type I interferons. In addition, the stimulation of
keratinocytes with RNase 7 and DNA induced an interferon-
beta (IFNß) dependent antiviral response which was sufficient to
counteract an infection of the keratinocytes with herpes-simplex
virus 1 (HSV-1). Taken together, there is increasing evidence that
RNase 7 is able to bind self-DNA immediately after its release and
induces a rapid DNA-mediated activation of keratinocytes (66)
and pDCs (60). Thus, RNase 7 may serve as an alarmin which
detects a disruption of the skin barrier by converting released
self-DNA into a danger signal (66).
Various immunomodulatory activities of other RNases
of the human RNase A superfamily have been described.
Examples are processing and clearance of RNA, activation of
immune cells, chemotactic activities, angiogenesis and neo-
vascularization, tissue remodeling and repair, wound healing
activity, and induction of apoptosis [reviewed in (67)]. Thus,
it is likely that RNase 7 exhibits additional, as yet unknown,
immunomodulatory functions. The known immunomodulatory
activities of RNase 7 are summarized in Table 2 (60, 65, 66).
Since the expression of RNase 7 is induced in inflammatory skin
diseases such as psoriasis and atopic dermatitis (see below) it is
likely that the immunomodulatory activities of RNase 7 may play
a role in these skin diseases. Furthermore, it is also of interest
to evaluate if the ribonuclease activity of RNase 7 may play a
role in degrading host RNA released from damaged cells thereby
controlling RNA-mediated inflammation during skin injury.
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TABLE 2 | Overview of the main findings regarding immunoregulatory activity of
RNase 7.
Findings References
Up-regulation of IFNα by human pDCs stimulated with
RNase 7 in mixture with self-DNA
(60)
Down-regulation of Th2 cytokines (IL-4, IL-13, and IL-5)
by activated human RNase 7-stimulated Th2 cells and
CD4+ T cells
(65)
RNase 7 stimulation of activated T cells results in a
reduced activity of the transcription factor GATA3
(65)
RNase 7 mediates sensing of self-DNA in human
keratinocytes leading to an antiviral immune response
(66)
ROLE OF RNase 7 IN SKIN DISEASES
Atopic Dermatitis
It has long been assumed that in the chronic inflammatory skin
disease atopic dermatitis (AD) the expression of AMP including
RNase 7 is impaired. This is based on the observation that
a Th2 cytokine predominance has been shown to negatively
regulate AMP expression (68, 69). In addition, comparative
studies showed a reduced expression of AMP in AD skin as
compared to psoriasis skin (70). However, especially for RNase
7, growing evidence reveals an increased expression in AD skin
as compared to healthy skin. By investigating skin biopsies
using quantitative real-time PCR, Gambichler et al. showed a
significantly higher expression of RNase 7 mRNA as compared
to expression in healthy skin (71). In addition, Harder et al.
investigated the protein expression of RNase 7 in skin biopsies
using immunostaining and ELISA of skin-derived washing fluids.
Both methods revealed an enhanced RNase 7 expression and
secretion in lesional skin of AD patients as compared to healthy
controls (23). In another study, Clausen et al. investigated RNase
7 protein expression in the uppermost skin layers using tape
stripping followed by ELISA measurements. In line with the
above mentioned studies they also found a higher expression of
RNase 7 in AD skin as compared to healthy skin (72). Taken
together, there is consistent evidence that expression of RNase
7 is induced in the skin of atopic dermatitis patients. The
consequence of this induction on diseases progression remains
to be analyzed in future studies.
As mentioned above, RNase 7 is able to downregulate Th2
cytokine production in CD4+ T cells. This effect was reduced in
CD4+ T cells derived from AD patients (65). These data suggest
that RNase 7 plays an important role to negatively regulate the
expression of Th2 cytokines, a function that may be disturbed in
AD thereby promoting a Th2 cytokine environment.
Filaggrin is an essential component of the skin barrier. A
deficiency of this protein can lead to an impaired skin barrier
function and this is assumed to be a major predisposing factor
in the development of AD (73). van Drongelen et al. used
3D epidermal models with filaggrin knockdown and infected
these with methicillin-resistant S. aureus (MRSA) bacteria. They
showed that IL-31 favored epidermal S. aureus colonization
by preventing the S. aureus-induced expression of RNase 7
and other AMP (26). IL-31 is a pruritus-causing cytokine with
increased presence in AD (74). Thus, enhanced levels of IL-31 in
AD may locally inhibit an adequate induction of RNase 7 in S.
aureus-infected areas.
Psoriasis
A high-performance liquid chromatography (HPLC)-based
analysis detected high amounts of RNase 7 and other AMP in
psoriatic scale extracts (24). In line with these data, analyses
of RNase 7 protein expression by immunohistochemistry and
ELISA revealed increased expression of RNase 7 in the lesional
skin of psoriasis patients (23). The increased amount of RNase 7
and other AMP in psoriasis may offer an explanation as to why
psoriasis patients do not often suffer from skin infections despite
the disturbed skin barrier (75).
One characteristic of psoriasis is the enrichment of pDCs in
lesional skin and their key role in driving the development of
the disease by the release of IFNα (76). As mentioned above,
Kopfnagel et al. showed that RNase 7 in complex with self-DNA
is a potent trigger of pDC-derived IFNα. Thus, an enhanced
production of RNase 7 may trigger inflammation in psoriasis
through increased production of IFNα (60). Similarly, the ability
of RNase 7 to activate an inflammatory and antiviral response in
keratinocytes in the presence of self-DNA may have implications
in skin diseases such as psoriasis and atopic dermatitis where
self-DNA derived from injured cells may be present in increased
amounts (66).
Dermatomycoses
Major fungal cutaneous infections are superficial tinea and
pityriasis versicolor which are caused by dermatophytes and
Malassezia spp., respectively. An immunohistochemistry study
from Brasch et al. investigated epidermal AMP expression
in skin biopsies from infected and healthy persons. RNase 7
staining was significantly more often positive in the stratum
granulosum of tinea than in the stratum granulosum of pityriasis
versicolor and normal skin (77). In concordance with these
findings, Firat et al. detected a high upregulation of RNase 7
expression in keratinocytes infected with T. rubrum (30). By
blocking the EGFR, the T. rubrum-mediated RNase 7 induction
in keratinocytes was significantly reduced. Interestingly, patients
with anti-EGFR therapy have a high prevalence of cutaneous
infections including those caused by dermatophytes such as T.
rubrum (78). One may speculate that the anti-EGFR therapy may
impair antifungal defense of the skin by inhibiting production of
AMP such as RNase 7.
S. aureus Skin Infections
As already described above, RNase 7 exhibits potent in vitro
anti-staphylococcal activity and ex vivo as well as in vivo studies
highlight an important role of RNase 7 to control the growth of S.
aureus. This gives rise to the speculation that RNase 7 may make
up a fundamental part of innate cutaneous defense to fight off S.
aureus infections and that a dysregulation of RNase 7 in general
enhances the susceptibility toward S. aureus infections. However,
this intriguing hypothesis has to be verified in further studies.
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Chronic, recurrent, and persistent infections caused by S.
aureus are often associated with the formation of the small-
colony variant (SCV) phenotype. SCV have a longer generation
time leading to small colonies on agar plates. It is believed that
a switch from the wild-type phenotype to a SCV phenotype
makes it possible for S. aureus to escape from host defense
and to spread the infection (79). To proof the hypothesis that
SCV are less susceptible to the cutaneous AMP-mediated killing
activity, Gläser et al. used clinical S. aureus SCV strains and
exposed them to either AMP directly or to stratum corneum
extracts from healthy donors. In both setups the killing activity
toward S. aureus isolates displaying the SCV phenotype was
markedly reduced (43). These experiments demonstrated a less
susceptibility of SCV to the antimicrobial activity of RNase 7
and other human skin-derived AMP. Thus, switching into the
SCV phenotype may help S. aureus to subvert cutaneous innate
defense through a higher resistance towardAMP such as RNase 7.
An increasing threat is the spread of MRSA. MRSA acquired
resistance mechanisms against many antibiotics commonly used
to treat S. aureus skin infections. In human skin equivalents
infected with MRSA the expression of RNase 7 was induced, in
particular in wounded skin (28). Of note, RNase 7 is able to
dampen the growth of MRSA in vitro (12) and own unpublished
results. These data indicate an important role of RNase 7 as
cutaneous defense factor to control the growth of MRSA. It
is an interesting hypothesis that patients with an impaired
RNase 7-based cutaneous defense are more susceptible to the
spread of virulent S. aureus including MRSA. Notably, the highly
FIGURE 2 | Role of RNase 7 in skin defense.
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virulent strain USA300, a highly pathogenic MRSA causing
severe skin and soft tissue infections, displays a comparatively
low susceptibility toward the anti-staphylococcal activity of
stratum corneum extracts (42). If a decreased activity of RNase
7 against USA300 contributes to this effect is speculative but
not unlikely. This is supported by the fact that RNase 7 is a
major component of the anti-staphylococcal activity of stratum
corneum skin extracts (25).
As discussed above the presence of cationic amino acid
residues endows RNase 7 with a positively charged N-terminal
cluster that is required for antimicrobial activity. It is known that
S. aureus has the capability to reduce its susceptibility toward
the action of cationic AMP through the reduction of its negative
surface charge. This can be achieved by the incorporation of
D-alanine in its teichoic acids, a mechanism that lowered the
susceptibility of S. aureus toward several skin-derived AMP
including RNase 7 (42). It remains to be determined if the use
of such strategies to lower the sensitivity toward the bactericidal
activity of RNase 7 are associated with a higher pathogenic
potential of distinct S. aureus strains.
Wounds
An intact skin barrier is essential for the protection against
potential pathogenic microorganisms. In case of wounding, a
rapid and potent defense is pivotal. In this regard, it has been
shown that RNase 7 is rapidly released on the skin surface
after experimental superficial barrier disruption (23). In contrast,
Dressel et al. detected no increase of RNase 7 expression in
the margins of chronic wounds, whereas the expression of the
AMP hBD-2 and psoriasin was strongly induced. This led to the
hypothesis that an insufficient expression of RNase 7 in chronic
wounds may contribute to disturbed wound healing (80). Zanger
et al. reported on a 50% lower RNase 7 gene expression in
skin 3 days after sterile wounding (81). This in turn supports
the idea that RNase 7 acts primarily as a component of the
early and primary cutaneous defense response after injury (81).
Clearly, more studies are needed to decipher the antimicrobial
and immunomodulatory functions of RNase 7 in wounded skin.
Mycobacterial Infections
It has been reported that RNase 7 exhibits antimicrobial activity
againstMycobacterium vaccae at low micromolar concentrations
(40). Furthermore, infection of airway epithelial cells with
Mycobacterium tuberculosis led to induction of RNase 7
expression and an intracellular association of RNase 7 with
Mycobacterium tuberculosis (50). This may suggest a direct
antimicrobial effect of RNase 7 on Mycobacterium tuberculosis,
but this has to be confirmed in further studies. Nevertheless, these
initial studies give rise to the hypothesis that RNase 7 may play
a role in infections caused by mycobacteria. Thus, it remains to
be shown whether RNase 7 may also be involved in cutaneous
mycobacterial defense (82).
OUTLOOK
The role of RNase 7 in the skin is still emerging. However,
as outlined in this review there is increasing evidence that
RNase 7 plays an important role in innate cutaneous defense.
This is mediated by the antimicrobial and immunomodulatory
characteristics of RNase 7 (Figure 2 summarizes the role of
RNase 7 in skin defense). It is likely that future studies will reveal
novel immunomodulatory functions of RNase 7 and shed light
on the as yet poorly understood importance of the enzymatic
activity of RNase 7 in a physiological context. Moreover, it is
of importance to further elucidate the potential link between
specific infectious and inflammatory diseases and an impaired
expression and/or function of RNase 7.
As mentioned in this review, functional studies as well as
in vivo observations identified RNase 7 as a crucial factor
to control the growth of the major cutaneous pathogen S.
aureus. There is also evidence that other pathogens such as P.
aeruginosa are affected by RNase 7. Thus, it is an interesting
hypothesis that RNase 7 or optimized derivatives based on
RNase 7 may have a high potential as anti-invectives. In
this regard, the in vitro activity of RNase 7 against multi-
resistant bacteria (12) may offer a promising alternative to
fight off bacteria that are hard to kill by common antibiotics.
Moreover, the targeted design of chimeric constructs combining
selected parts of different molecules with high antimicrobial
and ribonuclease activity, as recently reported for an RNase
3/1 hybrid construct (83), is a promising strategy. However,
when considering RNase 7 for application as a therapeutic
drug it is of great importance to evaluate the possibility
that an excessive medical use of RNase 7 may induce the
emergence of bacteria with an acquired resistance toward RNase
7. Such scenario could threaten our own innate host defense.
In addition, the influence of immunomodulatory activities as
well as the interaction of RNase 7 with the microbiota have
to be considered when using RNase 7 in the treatment or
prophylaxis of infections. In the case of atopic dermatitis,
where S. aureus and elevated Th2 cytokines are major drivers
of the disease, the capability of RNase 7 to kill S. aureus
together with its influence on T cells to dampen secretion
of Th2 cytokines may qualify RNase 7 as a beneficial drug
to treat atopic dermatitis. Finally, the inducibility of RNase
7 gives rise to the speculation that a targeted induction of
RNase 7 may offer a useful treatment or prophylactic option.
Clearly, more studies are needed to unravel the physiological
role of RNase 7 and to define its role in diseases and
as a potential drug.
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